Study_Mentioned
stringlengths 3
205
⌀ | Product_Mentioned
stringlengths 3
429
⌀ | Company_Mentioned
stringlengths 3
288
| Indication_Mentioned
stringlengths 2
111
| Non_Social
int64 1
1
| Tag
stringlengths 2
1.13k
⌀ | Adjusted_Date
stringlengths 11
16
| Conversation_Id
float64 422,000,000B
1,680,000,000B
| Clean_Tweet
stringlengths 1
298
⌀ | Profile_Bio
stringlengths 1
185
⌀ | Class
stringclasses 6
values | User_Type
stringclasses 17
values |
|---|---|---|---|---|---|---|---|---|---|---|---|
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/6/2022 9:36 | 1,530,000,000,000,000,000 | medical oncologist dr. sylvia adams discusses the drug enhertu with . the drug could open up new treatment possibilities for thousands of patients with advanced breast cancer. the findings were featured at & published in . read more : | We combine visionary thinking and compassionate care with the science of treating cancer. An NCI-designated Comprehensive Cancer Center, part of NYU Langone. | Company / Organization | Hospital / Clinic |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'trastuzumab', 'destiny-breast04'] | 6/6/2022 10:34 | 1,530,000,000,000,000,000 | #asco22 news: destiny-breast04 practice changing for her2-low metastatic breast cancer. read our report of the trastuzumab deruxtecan study presented by shanu modi of , with comments from and patricia lorusso | Medicine Matters #oncology publishes the latest news, commentary, research, and educational resources in a range of topics across oncology. | Company / Organization | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'destiny-breast04'] | 6/6/2022 11:06 | 1,530,000,000,000,000,000 | i ll never forget your masterful understatement in response to destiny-breast04 s plenary applause & standing ovation: i think they liked it" | Director, GI Oncology, @Intermountain. Interests: neuroendocrine tumors, cancer syndromes, empathy (even had a Whipple myself). Tweets my own. | Individual | HCP |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'corin', 'enhertu'] | 6/6/2022 11:42 | 1,530,000,000,000,000,000 | a few sobering points amid all the #asco22 excitement over enhertu benefit in her2-low breast cancer: there's still much variability in ihc 0 and 1+ scoring ... and the trial enrollment didn't live up to the meeting theme of "advancing equity" | Journalist: Personalized medicine, genomics, cancer; Managing editor: @PrecOncNews
https://t.co/t2jQRuYQgf
@GenomeWeb
https://t.co/MOrpOLPAKt | Individual | Media / News |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/6/2022 11:51 | 1,530,000,000,000,000,000 | stunning results in breast cancer enhertu lowered risk of death / progression by 50% vs. chemo. my friend in the room at asco said there was a standing ovation and even tears at the presentation | Healthcare/biotech. Assistant Professor Adjunct at @Yale | MPhil/PhD, @IIPP_UCL | Cofounder, @Azitrainc | Partner, Bios Partners | Forbes 30 | Opinions mine. | Individual | Research / Science |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['db04'] | 6/6/2022 12:53 | 1,530,000,000,000,000,000 | excited to see db04. our study suggested her2low bc may be more sensitive to chemotherapy and support further development of anti her2low agent.
no sig racial diff in her2 low prevalence. no sig diff in oncotype rs between her2-low and her2 zero. #asco22 | Hem/Onc Fellow @RoswellPark
Interested in patient centered care, survivorship/policy/outcome research
SoochowUniv' MD 14, MPH 16 @yalesph , IM 2020 @msm_msw | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['congrat', 'db04', 'breast', 'mbc'] | 6/6/2022 14:17 | 1,530,000,000,000,000,000 | what a powerful moment that will remain in the history of #breast #oncology.
congratulations dr. shanu modi for the standing ovation for presenting practice-changing db04 results: t-dxd doubles pfs and improves os by >6m in her2-low mbc.
#asco22 #breastcancer | Evidence-based, educational resources for the oncology community. Authored exclusively by a leading international faculty of oncology. | Company / Organization | Healthcare |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'tnbc', 'breast', 'destiny-breast04'] | 6/6/2022 14:44 | 1,530,000,000,000,000,000 | findings yesterday at #asco22 likely create new treatment target for people with her2-low (ihc 1+ and 2+) hr+ #metastaticbreastcancer, and possibly for those with mtnbc as well. learn more about the landmark destiny-breast04 trial in our asco coverage: | The mission of Living Beyond Breast Cancer (LBBC) is to connect people with trusted breast cancer information and a community of support. | Company / Organization | Advocacy / Charity |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other,gi | 1 | ['paradigm', 'congrat', 'db04'] | 6/6/2022 15:48 | 1,530,000,000,000,000,000 | practice changing is often thrown around nonchalantly. not here. #db04 is #paradigmshifting congrats to investigators and my friend #asco22 | Chief MedOnc @SylvesterCancer. Helping improve Cancer Control in LMICs. Editor-in-Chief @JCOGO_ASCO, Board Member @UICC - co-chair #ATOMcoalition | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destinybreast04', 'bcsm', 'destiny,breast,4', 'breast'] | 6/6/2022 16:24 | 1,530,000,000,000,000,000 | dr. modi and #destinybreast04 may have won #asco22 but me and my breastie been on this page sinceeee pre-covid #bcsm #asco2022 #endcancer #breastcancer | Breast Oncologist @mdandersonews.Proudly @UF @UFHealthCancer trained. Do GOOD. Advocate for #Genderequity #Equality #EndCancer #Science #bcsm #ASCO. Views =own | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['db04'] | 6/6/2022 16:24 | 1,530,000,000,000,000,000 | my thoughts on db04 for discussion: - sequencing of therapy. - bystander effect or additional her2 target mechanism? - better test than ihc to identify her2 low? - it will likely pan-out to all her2 low cancers! #asco2022 #asco22 | ???????? ?? ??????? - ?????? ???????? Medical Oncologist #breastcancer. MD Anderson Alumni “All tweets are my own and RT?endorsement” | Individual | HCP |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'astrazeneca', 'daiichi'] | 6/6/2022 18:44 | 1,530,000,000,000,000,000 | what is all that noise in the exhibit hall? celebrating showing data from a breakthrough breast cancer drug enhertu, developed by and at #asco22. patients on enhertu lived 7 months longer than on standard chemo. | Wife, Mother, Physician | Individual | HCP |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/6/2022 19:33 | 1,530,000,000,000,000,000 | enhertu could transform #breastcancer treatment, landmark her2-low trial suggests. #asco22 #asco2022 | The leading online provider of #CME, #CNE, #CE, and #CPE across 30+ medical specialties to support health professionals in improving patient care. | Company / Organization | Healthcare |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/6/2022 20:44 | 1,530,000,000,000,000,000 | enhertu could transform #breastcancer treatment, landmark her2-low trial suggests. #asco22 | Latest medical news, articles, and features from Medscape Pharmacists. | Company / Organization | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destinybreast04', 'destiny,breast,4', 'breast'] | 6/6/2022 21:32 | 1,530,000,000,000,000,000 | standing ovation for the incredible results of the #destinybreast04 trial for her2 low breast cancer. #asco2022 #makingcancerhistory | IM Resident @metrohealthCLE| @cwru Case Western Reserve Uni| Aspiring Oncologist | Special interest in Oncderm & Melanoma| ???????? | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny-breast04', 'breast'] | 6/4/2022 9:44 | 1,530,000,000,000,000,000 | destiny-breast04 continues to be the most talked about session at #asco22 | Plan, consolidate data, and synthesize insights from life science conferences and social media with https://t.co/Fhm0QpaU5o, a product of @ZoomRx. | Bot / Aggregator | Media / News |
destiny-breast03 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast'] | 6/4/2022 13:27 | 1,530,000,000,000,000,000 | conclusions by dr on destiny breast 03. #asco22 #bcsm | (former) doctor, mother, woman LIVING with metastatic breast cancer. Grant reviewer. Conference goer. METAvivor board member. She/her. #NotDeadYet for 8 years | Individual | Advocacy / Charity |
destiny-breast03 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'destiny-breast03', 'breast'] | 6/4/2022 13:30 | 1,530,000,000,000,000,000 | reporting new data live from #asco22 more evidence of trastuzumab-deruxtecan s safety & utility in her2+ metastatic bc! the destiny-breast03 safety follow-up finds this combination s safety profile to be both tolerable & superior to trastuzumab-emtansine. | Real time, on-demand personalized cancer education and support through our online educational platform | Company / Organization | Healthcare |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'destiny-breast04', 'breast'] | 6/4/2022 20:22 | 1,530,000,000,000,000,000 | in anticipation of the results of destiny-breast04 being presented tomorrow, i thought i would share some information about fam-trastuzumab deruxtecan-nxki (t-dxd) and how it may differ from other her2-directed antibody drug conjugates in breast cancer, notably tdm-1. | Clinical Oncology Pharmacist @OHSUNews
Founder and President of Banyan Tree Clinics https://t.co/YXpxhLXWFu
Tweets and dog photos my own | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'mbc', 'bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 7:03 | 1,530,000,000,000,000,000 | half of pts (55%) with mbc categorized as her2- actually do express low levels of her2, and in these pts trastuzumab deruxtecan provides pfs and os benefit -- results from phase 3 destiny-breast04 [#asco22 plenary lba3] . #bcsm | Medscape Oncology provides breaking medical news, references for drugs, diseases, and procedures, and free CME. | Company / Organization | Media / News |
destiny-breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast'] | 6/5/2022 7:21 | 1,530,000,000,000,000,000 | trastuzumab deruxtecan in previously treated her2-low advanced breast cancer | #asco22 | The official account of Memorial Sloan Kettering Cancer Center, the Sloan Kettering Institute, and Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences | Company / Organization | Hospital / Clinic |
Not Tagged | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'mbc', 'bcsm', 'breast', 'enhertu'] | 6/5/2022 7:25 | 1,530,000,000,000,000,000 | game changer in her2 low mbc. i will be putting patients on this come tuesday. enhertu reduces risk of progression by 49% and risk of death by 34%. #bcsm #asco22 trastuzumab deruxtecan in previously treated her2-low advanced breast cancer | nejm | Breast & gyn med onc @valleyhospital in NJ. Focus on survivorship and ?????? onc. All opinions my own. Retweets not endorsements. Host of INTERLUDE podcast ?? | Individual | HCP |
destiny-breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'bcsm', 'breast'] | 6/5/2022 7:49 | 1,530,000,000,000,000,000 | trastuzumab deruxtecan in previously treated her2-low advanced breast cancer | nejm a game changer indeed #asco22 #t-xd#bcsm#asco#modi#nejm. strong work, we are all looking forward to this | Breast Oncologist @mdandersonews.Proudly @UF @UFHealthCancer trained. Do GOOD. Advocate for #Genderequity #Equality #EndCancer #Science #bcsm #ASCO. Views =own | Individual | HCP |
destiny-breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast'] | 6/5/2022 7:51 | 1,530,000,000,000,000,000 | practice changing monday morning! trastuzumab deruxtecan in previously treated her2-low advanced breast cancer | nejm | Dr. Patt is a med onc, healthcare informatics specialist, and health policy expert @TexasOncology @TheUSONetwork @DellMedSchool. All views are my own. | Individual | HCP |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', '$azn', '$dsnky'] | 6/5/2022 8:41 | 1,530,000,000,000,000,000 | enhertu nearly halves risk of disease progression in her2-low breast cancer study $azn $dsnky #asco22 | #IME #CME #healthcare #innovation #DotConnector https://t.co/Ag09XUbNP3 | Individual | Blogger / Random / Other |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 8:51 | 1,530,000,000,000,000,000 | destiny-breast04 is a game changer with a novel concept of effective her2 targeting in her2 low breast cancer. i am looking forward to the presentation later today at #asco22 | Medical Oncologist, Cancer Researcher, Drug Developer, ex-@MDAndersonNews, Chief Medical Officer @MonteRosaTx. Views are mine. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'breast', 'destinybreast04'] | 6/5/2022 8:51 | 1,530,000,000,000,000,000 | #asco22 - #destinybreast04
we saw it coming, but it still swept us away.
re-testing her2 status on metastases in her2-negative mbc pts with an original her2-0 report is now of the utmost importance. | Ricercatore Oncologia Medica | Individual | HCP |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['solid tumor', 'enhertu'] | 6/5/2022 8:57 | 1,530,000,000,000,000,000 | it s not so long ago that some experts questioned if antibody-drug conjugates would have a future in solid tumor indications. the hype cycle at its best. good to see that solid science in the end prevails: enhertu news at #asco22 | MedChem @Merckgroup; drug discovery, oncology, targeted protein degradation, chemical probes; CDU, Hannover96, literature, traveling; my own views ???????????? | Individual | Pharma / Biotech |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 9:07 | 1,530,000,000,000,000,000 | destiny-breast04 trial a gamechanger for treatment of metastatic breast cancer patients. #asco2022 | Horse and dog crazy, Grandmother who loves her family! Dragon boat racer, Metastic Breast Cancer Vivor and Advocate! | Individual | Advocacy / Charity |
Not Tagged | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'daiichisankyous', 'astrazenecaus', 'astrazeneca'] | 6/5/2022 9:41 | 1,530,000,000,000,000,000 | if tdxd isn t approved for her2 low won t insurance companies balk at paying for it? and it ain t cheap. will and seek fda approval in her 2 low? #asco22 #bcsm #financialtoxicity | (former) doctor, mother, woman LIVING with metastatic breast cancer. Grant reviewer. Conference goer. METAvivor board member. She/her. #NotDeadYet for 8 years | Individual | Advocacy / Charity |
destiny-breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | Not Tagged | 1 | ['trastuzumab'] | 6/5/2022 9:52 | 1,530,000,000,000,000,000 | i just uploaded asco 2022: trastuzumab deruxtecan vs. treatment of physician's choice in her2-low unresectable a | Conference reports (Webcasts, Slides & Videos) in German and English about clinical oncology | Bot / Aggregator | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast', 'destiny-breast04', 'astrazeneca'] | 6/5/2022 11:06 | 1,530,000,000,000,000,000 | much-anticipated news from presented by dr. shanu modi: results of destiny-breast04, a randomized, phase 3 study: trastuzumab deruxtecan versus treatment of physician s choice in patients with her2-low unresectable and/or metastatic breast cancer #asco22 b1 2:17pm | Creating Aha! Moments In Healthcare
IDEOlogy Health is leading the change in how healthcare professionals connect and stay up-to-date on the latest advancements | Company / Organization | Consulting / Analytics |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/5/2022 11:52 | 1,530,000,000,000,000,000 | az, daiichi set new standard in her2-low breast cancer with enhertu #asco22 data, via 's : | Executive Editor, @BioCentury. Jersey boy happily ensconced in Cali. Dad. Failed poet. Devoted Iggles fan. Cats. @Princeton, @SAISHopkins alum. Opinions? Mine. | Individual | Publication / Journal |
Dramatic | Not Tagged | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'astrazeneca'] | 6/5/2022 12:58 | 1,530,000,000,000,000,000 | 'dramatic' study results for astrazeneca, daiichi drug suggest new way to treat aggressive breast cancer via | A Real Democrat | Individual | Blogger / Random / Other |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['lba3 '] | 6/5/2022 14:17 | 1,530,000,000,000,000,000 | dr. modi lba3 #asco22: the results first then the data... | Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi | Individual | Professional |
destiny-breast03 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['enhertu'] | 6/5/2022 14:19 | 1,530,000,000,000,000,000 | (waiting for the first destiny or enhertu pun) #asco22 | Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi | Individual | Professional |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['lba3 '] | 6/5/2022 14:20 | 1,530,000,000,000,000,000 | dr. modi lba3 #asco22: hr+ pts had to have endocrine refractory disease | Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi | Individual | Professional |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'destinybreast04'] | 6/5/2022 14:21 | 1,530,000,000,000,000,000 | changing the breast cancer game #bcsm #her2 #asco22 #destinybreast04 | Hematology/Medical Oncology Fellow at University of Illinois Chicago @UIHealth | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['lba3 '] | 6/5/2022 14:24 | 1,530,000,000,000,000,000 | dr. modi lba3 #asco22: early separation of pfs curves in hr+ and in all pts (in fact curves, are nearly identical) | Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi | Individual | Professional |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny-04'] | 6/5/2022 14:25 | 1,530,000,000,000,000,000 | #asco22 plenary destiny-04 | Oncologist | Researcher | ColorectalCancer #CRCSM???????@MayoClinic @PittTweet Alum; ??#ctDNA #LiquidBiopsies??#PrecisionOncology ViewsMy Own. COI @ASCO #ASCO22 | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['lba3 '] | 6/5/2022 14:26 | 1,530,000,000,000,000,000 | dr. modi lba3 #asco22: os curves showed a gain in survival of 6.6 mos in favor of t-dxd | Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi | Individual | Professional |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'fierce', 'astrazeneca'] | 6/5/2022 14:27 | 1,530,000,000,000,000,000 | fiercepharma: asco: astrazeneca, daiichi's enhertu could transform breast cancer treatment with landmark her2-low show. via | Having fun while I can: DIY, photography, gardening, motorhome travelling. BN member.
Ex RAF ???? | Individual | Blogger / Random / Other |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 14:27 | 1,530,000,000,000,000,000 | destiny-breast04 trials results at plenary. lacking representation of patients of color (hispanic/black) #asco22 | Narjust Duma, MD, (@NarjustDumaMD) #LCSM Oncologist from @DanaFarber, takes over our Twitter today to discuss #ASCO22. | Company / Organization | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'destinybreast04'] | 6/5/2022 14:28 | 1,530,000,000,000,000,000 | #destinybreast04 t-dxd changing the face of breast cancer management #bcsm #asco22 #ascoplenary | Breast Onc/Genetics enthusiast @BillingsClinic Chief Fellow @UNM Chief Resident @Einsteinhealth Opinions mine She/Her #IMG #MedEd #MedicareForAll #Oncology | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | thoracic,other | 1 | ['lung', 'lba3 '] | 6/5/2022 14:29 | 1,530,000,000,000,000,000 | dr. modi lba3 #asco22: t-dxd rx discontinuation for lung toxicity was 8.2% | Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi | Individual | Professional |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['tnbc', 'mbc', 'bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 14:30 | 1,530,000,000,000,000,000 | destiny-breast04: t-dxd vs treatment of physician's choice in her2-low breast cancer (her2 ihc 1+ or 2+/fish-). pfs/os benefit in hr+, tnbc, and across all subgroups. impacts ~50% of all patients with mbc. shanu modi of #bcsm #asco22 | Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destinybreast04'] | 6/5/2022 14:31 | 1,530,000,000,000,000,000 | so exciting dara of the #destinybreast04 trial presented right now at #asco22 this result belongs to the remarkable moments in #breastcancer #therapy | advocate, speaker, medical journalist, Founder: German Breast Cancer Ass. (Brustkrebs Deutschland e.V.), Director of the General Assembly ABC Global Alliance | Individual | Advocacy / Charity |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['tnbc', 'breast', 'destiny-breast04'] | 6/5/2022 14:31 | 1,530,000,000,000,000,000 | #asco22. destiny-breast04. tdxd shows benefit in herlow breast cancer patients - impressive results - practice changing!!! # tnbc amazing results | Breast oncologist, Director of Cancer Center @MethodistHosp @HMethodistMD#bccww#bcsm#cancer | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny breast04', 'breast'] | 6/5/2022 14:31 | 1,530,000,000,000,000,000 | destiny breast04 #ascoplenaryseries #asco22 for almost a minute and standing ovation!! | Wife, Mom, Heme-Onc fellow @KUcancercenter, Internal Medicine Resident UICOMP, MedEd enthusiast, love heme-onc, Tweets are my own. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['lba3 '] | 6/5/2022 14:32 | 1,530,000,000,000,000,000 | dr. modi lba3 #asco22: extended applause for the destiny abstract "welcome back to a live meeting" | Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi | Individual | Professional |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 14:32 | 1,530,000,000,000,000,000 | the applause for destiny-breast04 is well deserved and amazing!! #asco22 | Medical Oncologist, Chair of Internal Medicine at Cleveland Clinic Akron General. Tweets are my own. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destinybreast04'] | 6/5/2022 14:32 | 1,530,000,000,000,000,000 | huge standing ovation for #destinybreast04- important trial looking at refractory disease, median of 3 lines of treatment, with os benefit #asco22 | @stanfordcancer Clinical Assis Prof.+ Assoc dir. of cancer quality, via @BIDMC_IM, Thoracic Onc + merging QI with health equity, brunch lover, tweets my own | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 14:33 | 1,530,000,000,000,000,000 | prolonged applause and standing ovation in the room for destiny-breast04 t-dxd. i guess this was well received. - #asco22 | Professor of medicine | medical oncologist | head EH clinical school | Chair, ANZUP | husband, father, grandfather, blessed | want to make a positive difference | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'destinybreast04'] | 6/5/2022 14:33 | 1,530,000,000,000,000,000 | standing ovation for dr shanu modi!! #asco22 #bcsm #destinybreast04 | Hematology/Medical Oncology Fellow at University of Illinois Chicago @UIHealth | Individual | HCP |
destiny-breast04 | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'destinybreast04'] | 6/5/2022 14:33 | 1,530,000,000,000,000,000 | destinybreast04 showing enhertu benefit in her2-low advanced breast cancer patients gets rare standing ovation at #asco22 | Journalist: Personalized medicine, genomics, cancer; Managing editor: @PrecOncNews
https://t.co/t2jQRuYQgf
@GenomeWeb
https://t.co/MOrpOLPAKt | Individual | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 14:33 | 1,530,000,000,000,000,000 | standing ovation for fantastic destiny-breast04 results at #asco22 | oncology, genomics, data @sema4 | Individual | Consulting / Analytics |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny04'] | 6/5/2022 14:34 | 1,530,000,000,000,000,000 | the presentation of destiny04 made the b1 hall electrifying #asco22 new era for patients, but still ild seen in 8% of pts | Proud to be Puerto Rican, mother, wife and oncologist, representing community oncologist @ASCO BOD 21-25, @TheStartcenterforcancercare. Opinions are my own. | Individual | HCP |
Not Tagged | Not Tagged | astrazeneca,daiichi sankyo | Not Tagged | 1 | ['enhertu', '$azn'] | 6/5/2022 14:35 | 1,530,000,000,000,000,000 | standing ovation at #asco22 ! #enhertu $azn | Health is a state of mind. Practicing #yoga. Fan of @onepeloton, @Eagles @SJUHawks, and all things #NOLA. | Individual | Blogger / Random / Other |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 14:36 | 1,530,000,000,000,000,000 | there was a literal standing ovation for destiny-breast04 #asco22 | PhD microbiology | medical writer | immunotherapy | ??????? | ?? | ??????? | ?????? | he/him/his | affiliated w/ @dadaohou | mostly irreverent | Individual | Research / Science |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'destiny-04', 'energy'] | 6/5/2022 14:37 | 1,530,000,000,000,000,000 | absolutely incredible for mbc, the energy right now is palpable! proud to make destiny-04 results my first ever tweet! #asco22 | null | Individual | Research / Science |
Not Tagged | trastuzumab | astrazeneca,daiichi sankyo | Not Tagged | 1 | ['herceptin'] | 6/5/2022 14:37 | 1,530,000,000,000,000,000 | this standing ovation and enthusiasm reminds me of your discussion of the herceptin adjuvant trials #asco22 | null | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 14:37 | 1,530,000,000,000,000,000 | absolutely incredible, practice-changing breast cancer research (destiny-breast04) presented by dr. shanu modi to a standing ovation at #asco22 it was so inspirational to me as an incoming heme/onc fellow and aspiring breast oncologist! the nejm article: | @BCM_InternalMed QI chief resident, future @washuheme fellow, mom of 3. I love stories in all forms. All opinions my own. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['inspire', 'bcsm', 'breast', 'destinybreast04'] | 6/5/2022 14:37 | 1,530,000,000,000,000,000 | another standing ovation at #asco22 after sabcs2021 for t-dxd. as the daughter who lost her mother to her2 positive breast cancer practice changing research like this is what inspires early oncologists like me! #bcsm #onctwitter #destinybreast04 | Breast Onc/Genetics enthusiast @BillingsClinic Chief Fellow @UNM Chief Resident @Einsteinhealth Opinions mine She/Her #IMG #MedEd #MedicareForAll #Oncology | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny-04', 'breast'] | 6/5/2022 14:38 | 1,530,000,000,000,000,000 | standing ovation for destiny-04 trial with t-dxd in her2 low breast cancer today. practice-changing results, undoubtedly. spectacular os benefit in hr+ and hr- disease. the asco plenary session remains the holy grail of clinical research in our field. | Passionate medical oncologist with experimental + public health agenda heading the Dpt. of General Medical Oncology + Lab. of Exp. Oncology at UZ/KU Leuven (BE) | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny-04', 'bcsm'] | 6/5/2022 14:38 | 1,530,000,000,000,000,000 | wow destiny-04 t-dxd in her2-low metbc #asco22 #bcsm. standing ovation | Cancer Research Patient Advocate at UNC Lineberger CCC. Breast & Liver cancer, clinical trials, PROMs, #SciComm Featured Voice #ASCO22 FCOI: https://t.co/PzlQKUfjUw | Individual | Advocacy / Charity |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destinybreast04'] | 6/5/2022 14:39 | 1,530,000,000,000,000,000 | key now will be to progress and redefine her2 1+ subpopulation regarding destinybreast 04 results #asco22 #destinybreast04 | null | Individual | HCP |
DESTINY-Breast04 | trastuzumab | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast'] | 6/5/2022 14:40 | 1,530,000,000,000,000,000 | this data will be practice-changing! shanu modi #asco22 trastuzumab-deruxtecan - a new standard of care for her2low hr+/her2- metastatic #breastcancer #brustkrebs | Praxisrelevantes Wissen für Ärztinnen und Ärzte | Hier twittert die größte deutschsprachige Expertencommunity mit über 190.000 Mitgliedern aus ???? ???? ???? | Individual | Blogger / Random / Other |
destiny-breast04 | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'breast', 'enhertu', 'destiny-breast04', 'astrazeneca'] | 6/5/2022 14:41 | 1,530,000,000,000,000,000 | standing ovation for dr shanu modi presenting destiny-breast04. practice changing for #mbc #her2low #asco22 #enhertu | Creating Aha! Moments In Healthcare
IDEOlogy Health is leading the change in how healthcare professionals connect and stay up-to-date on the latest advancements | Company / Organization | Consulting / Analytics |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny breast04', 'breast'] | 6/5/2022 14:45 | 1,530,000,000,000,000,000 | impressive results #destiny breast04 #asco22 improvement of pfs and os safety profile new standard treatment in patients with her2 low metastatic breast cancer | Medical oncologist | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'breast', 'destiny-breast04'] | 6/5/2022 14:50 | 1,530,000,000,000,000,000 | the results of destiny-breast04 live from #asco22 did you hear? the phase 3 trial of a her2-directed therapy is the first to show a statistically significant and clinically meaningful benefit in pfs and os vs tpc. an exciting new treatment for her2-low mbc on the horizon! | null | Company / Organization | Consulting / Analytics |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'breast', 'destiny-breast04'] | 6/5/2022 14:50 | 1,530,000,000,000,000,000 | the results of destiny-breast04 live from #asco22 did you hear? the phase 3 trial of a her2-directed therapy is the first to show a statistically significant and clinically meaningful benefit in pfs and os vs tpc. an exciting new treatment for her2-low mbc on the horizon! | Real time, on-demand personalized cancer education and support through our online educational platform | Company / Organization | Healthcare |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destinybreast04'] | 6/5/2022 14:51 | 1,530,000,000,000,000,000 | my first asco and i'm glad to be facing the making of a history #asco22 #destinybreast04 | Medical/Clinical Oncologist - Todua Clinic,
ESMO Young Oncologists' and Global Policy committee,
ESO Ambassador,
President of Georgian School of Oncology | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 14:52 | 1,530,000,000,000,000,000 | standing ovation to the destiny-breast04 trial #asco22.
the future of breast- oncology!!! | Addressing cancer health care disparities, one person at a time.
Prospecting Hematology/Oncology Fellow come 2023 | Individual | HCP |
DESTINY-Breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['enhertu', '$azn'] | 6/5/2022 14:53 | 1,530,000,000,000,000,000 | db-04 reviewer p lorusso's conclusions for #asco22 and enhertu... and another big round of applause... $azn and $dskny got to be pretty pleased right now. | Pharma and biotech reporter, found a home at Evaluate Vantage. | Individual | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['tnbc', 'sequence,(-consequence)', 'lba3 '] | 6/5/2022 14:53 | 1,530,000,000,000,000,000 | lba3 discussion: how to sequence t-dxd in her2 low and tnbc? need to learn more about mechanisms of resistance #asco22 | Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi | Individual | Professional |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 14:53 | 1,530,000,000,000,000,000 | standing ovation for destiny-breast04 and this awesome quote. that os benefit #asco22 #bcsm | Team bad blood?? Bugs and drugs?? ||
U of Michigan?? & UCSF?? trained ||
Stanford?? Views are my own?? ||
Food blogger on the side?? | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny breast04', 'breast'] | 6/5/2022 14:53 | 1,530,000,000,000,000,000 | applauds applauds and applauds #destiny breast04
#ascoplenaryseries #asco22 our destiny is written by us. | Wife, Mom, Heme-Onc fellow @KUcancercenter, Internal Medicine Resident UICOMP, MedEd enthusiast, love heme-onc, Tweets are my own. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny 04', 'breast'] | 6/5/2022 14:54 | 1,530,000,000,000,000,000 | the world of breast cancer just changed #asco2022 destiny 04 trial!! game changing! life changing! tdx-d rocks.... | Physician scientist in the making | Individual | HCP |
Not Tagged | Not Tagged | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'astrazeneca'] | 6/5/2022 14:55 | 1,530,000,000,000,000,000 | researchers: breast cancer drug could help more patients - aol: * researchers: breast cancer drug could help more patients aol * enhertu dramatically extends survival in breast cancer patients stat * asco: astrazeneca, daiichi's enhertu could | Cartomancers ?? ?? can tell secrets from ordinary playing cards, and we are them. https://t.co/zNSIbKQfdy | Individual | Blogger / Random / Other |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destinybreast04'] | 6/5/2022 14:59 | 1,530,000,000,000,000,000 | standing ovation for dr. shanu modi/destinybreast04 trial results at #asco22! watch for our coverage of this practice-changing data at | Medical journalist. Writer. Believer in love and hope and science. Ally. Views my own. She/Her | Individual | Publication / Journal |
DESTINY-Breast04 | trastuzumab Deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast'] | 6/5/2022 15:02 | 1,530,000,000,000,000,000 | trastuzumab deruxtecan in previously treated her2-low advanced breast cancer receives a standing ovation at #asco2022 #destinyb4 | PGY-II in Internal Medicine @Aurora_Health in Milwaukee, Wisconsin. Hopeful future Medical Oncologist/Hematologist. #MedTwitter | Individual | HCP |
Not Tagged | Not Tagged | astrazeneca,daiichi sankyo | other | 1 | ['breast', '$azn', '$dsnky', 'astrazeneca'] | 6/5/2022 15:03 | 1,530,000,000,000,000,000 | $azn $dsnky dramatic' study results for astrazeneca, daiichi drug suggest new way to treat aggressive breast cancer via | News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities | Individual | Finance / Investment |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 15:06 | 1,530,000,000,000,000,000 | destiny-breast04 just got a standing ovation #asco22 | Biotech & Oncology | ????????| Part markets, part science, part snark | Personal opinions only, retweets aren't endorsements | Individual | Finance / Investment |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny04', 'bcsm'] | 6/5/2022 15:09 | 1,530,000,000,000,000,000 | what an exciting moment to be part of the standing ovation for destiny04 at #asco22 #bcsm | Hematology/Oncology Fellow @MountSinaiNYC | Individual | HCP |
Not Tagged | trastuzumab | astrazeneca,daiichi sankyo | Not Tagged | 1 | ['trastuzumab'] | 6/5/2022 15:12 | 1,530,000,000,000,000,000 | most people don t have access to trastuzumab | @stanfordcancer Clinical Assis Prof.+ Assoc dir. of cancer quality, via @BIDMC_IM, Thoracic Onc + merging QI with health equity, brunch lover, tweets my own | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny04', 'bcsm'] | 6/5/2022 15:15 | 1,530,000,000,000,000,000 | this destiny04 standing ovation was quite a roar! #asco22 #bcsm | OBR is an oncology-focused digital media company that provides news and information resources to oncology professionals. | Company / Organization | Media / News |
Not Tagged | Not Tagged | astrazeneca,daiichi sankyo | other | 1 | ['breast', '$azn', '$dsnky', 'astrazeneca'] | 6/5/2022 15:16 | 1,530,000,000,000,000,000 | icymi earlier: dramatic' study results for astrazeneca, daiichi drug suggest new way to treat aggressive breast cancer #asco22 $azn $dsnky | Biotech Journalist; Senior Editor, BioPharma Dive | Individual | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['tnbc', 'bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 15:34 | 1,530,000,000,000,000,000 | 2/ still it's uplifting to see survival benefit for hr- disease esp tnbc which needs more therapeutic options. destiny-breast04 #asco22 #bcsm | Mother of Warlords & Slayer of Cancers|Brst/Gyn #radonc @WeillCornell @nyphospital @nypbrooklyn | #globaloncology | #globalhealth|#MedEd|#gyncsm|#bcsm???????? | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 15:34 | 1,530,000,000,000,000,000 | 3/3 moving fwd, we need to keep an eye on toxicities. higher rates of nausea & 12% risk of pneumonitis noted on destiny-breast04. need to track rates of these and other toxicities in clinical settings. read more about the trial #asco22 #bcsm | Mother of Warlords & Slayer of Cancers|Brst/Gyn #radonc @WeillCornell @nyphospital @nypbrooklyn | #globaloncology | #globalhealth|#MedEd|#gyncsm|#bcsm???????? | Individual | HCP |
Not Tagged | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | Not Tagged | 1 | ['trastuzumab', 'enhertu'] | 6/5/2022 15:37 | 1,530,000,000,000,000,000 | the use of trastuzumab deruxtecan (enhertu ), a new her2-targeting antibody-drug conjugate, doubled progressi... | Physician-Scientist; Translational Oncologist https://t.co/8RMRruPhfx Director @BrownUCancer Associate Dean @BrownMedicine | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny 04', 'bcsm'] | 6/5/2022 16:03 | 1,530,000,000,000,000,000 | destiny 04 got a standing ovation, which was why we were thrilled that interviewed for #obroncology! stay tuned for amazing peer to peer insights! #asco22 #bcsm | OBR is an oncology-focused digital media company that provides news and information resources to oncology professionals. | Company / Organization | Media / News |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | Not Tagged | 1 | ['enhertu', '$azn'] | 6/5/2022 16:28 | 1,530,000,000,000,000,000 | how would you rate the $azn enhertu data presented at #asco22 in importance to improving biotech sentiment, if at all? | •Nerd •L/S HF PM •Value/Healthcare/Special Situations •Unfunny Memes **Personal Acct/Not Investment Advice/Not Your Financial Advisor/May Have Positions** | Individual | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'breast', 'destiny-breast04'] | 6/5/2022 16:47 | 1,530,000,000,000,000,000 | beautiful standing ovation for dr. modi today such a treat to learn about the results for the destiny-breast04 trial (also published in nejm today). first trial showing increased os + pfs in her2-low mbc treated with t-dxd (trial included her2- pts too)! #oncoalert #asco22 | PGY2 IM Resident. Heme-Onc Enthusiast. Special interest: GI Onc + Immunotherapy. Orangetheory fitness. Modern woman in med-balancing it all. *views are my own* | Individual | HCP |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'astrazeneca'] | 6/5/2022 16:54 | 1,530,000,000,000,000,000 | on the enhertu results, astrazeneca vp camille hertzka told me she 1st thought of patients & a friend w/her2-low breast cancer i thought, well, she s still responding to treatment, but if 1 day she fails, well, we have something for her." w/ | covering the science, people, $ & biotechs behind new meds @Endpts | Tips? klahucik@endpointsnews.com | asking Q's, jogging 26.2 | ?? ?? ?? | he/him ?????? | Individual | Media / News |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | Not Tagged | 1 | ['enhertu', '$azn', 'astrazeneca'] | 6/5/2022 17:19 | 1,530,000,000,000,000,000 | $azn #astrazeneca plc astrazeneca - asco and you shall get: enhertu delivers in-line with high expectations in db04 efficacy across both ihc 2+/ish- and 1+, but ild worse near-term positive, long-term supportive for share [...] #equity #stocks | @ResearchPool helps the buy-side, sell-side and corporates discover research quickly, streamline workflows and broaden distribution. #valuingknowledge | Company / Organization | Finance / Investment |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast'] | 6/5/2022 18:00 | 1,530,000,000,000,000,000 | fam-trastuzumab deruxtecan-nxki doubles progression-free survival in her2-low metastatic breast cancer - the asco post | Physician, Precision Oncology, Researcher, Cancer Expert, CEO Protean Biodiagnostics. Professor Oncology and Pathology. | Individual | Pharma / Biotech |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'destiny-04'] | 6/5/2022 18:13 | 1,530,000,000,000,000,000 | following the #asco22 meeting and the progress is palapable. destiny-04 trial in mbc (met with a standing ovation) and patient advocates presenting to a full house ( ) on #rwd in trials "a statistical difference is not the same as clincial benefit" | The next project of the International Cancer Genome Consortium; translating genomic knowledge to improve outcomes for people affected by cancer. #ThisIsICGCARGO | Company / Organization | Advocacy / Charity |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'astrazeneca'] | 6/5/2022 18:17 | 1,530,000,000,000,000,000 | asco: astrazeneca, daiichi s enhertu could transform breast cancer treatment with landmark her2-low show #asco22 | Get the Latest Social Media Buzz from #ASCO22!!! | Company / Organization | Media / News |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['tnbc', 'breast', 'enhertu'] | 6/5/2022 18:41 | 1,530,000,000,000,000,000 | #enhertu is not only the most active drug in most er+ advanced breast cancers, it is also the most active in er- her2 low (ie tnbc) #asco22 #azn #dskny | Provides consulting services to biopharmaceutical and healthcare organizations globally. Learn more at: https://t.co/TwHtYAbhWb | Company / Organization | Consulting / Analytics |
Not Tagged | Not Tagged | astrazeneca,daiichi sankyo | Not Tagged | 1 | ['$azn', '$dsnky', 'fierce'] | 6/5/2022 18:42 | 1,530,000,000,000,000,000 | for those looking for the cliffs notes on what $azn $dsnky presented at asco covered it well | Biotech, health policy, economic policy. | Bot / Aggregator | Media / News |